鞍石生物科创板IPO获得受理 拟募资24.5亿元

Core Viewpoint - Ansh Biotechnology Co., Ltd. has received acceptance for its IPO on the Sci-Tech Innovation Board, aiming to raise 2.45 billion yuan, focusing on innovative anti-tumor drugs to meet significant unmet clinical needs [1] Company Overview - Ansh Biotechnology is an innovative biopharmaceutical company that has entered the commercialization stage, specializing in diseases like cancer with high unmet clinical needs [1] - The company aims to enhance the quality of life for patients through efficient self-research and development of high-quality innovative anti-tumor drugs [1] Financial Performance - The financial data for Ansh Biotechnology shows the following projected revenues and net profits: - 2022: Revenue of approximately 0 million yuan, net profit of -163.68 million yuan - 2023: Revenue of approximately 12.96 million yuan, net profit of -282.72 million yuan - 2024: Revenue of approximately 71.66 million yuan, net profit of -478.71 million yuan - Q1 2025: Revenue of approximately 64.04 million yuan, net profit of -91.65 million yuan [1] Product Development - As of the signing date of the prospectus, Ansh Biotechnology's main product, Wanbi Rui (Bertinib), has received approval for three indications in China - The company has also successfully submitted a new drug application for Andai Aitini and has been granted priority review and approval status [1]